exRNAdisease

Entry Detail

---



General Information

Database ID: exR0275685 RNA Name: hsa-miR-513a-5p RNA Type: miRNA Chromosome: chrX Starnd: - Coordinate: Start Site(bp): 147213538 End Site(bp): 147213555 External Links: hsa-miR-513a-5p

Disease Information

Disease Name: Advanced Adenoma Disease Category: Cancers MeSH ID: D000236 Type: Neoplasms/Neoplasms, Glandular and Epithelial Alias: Adenoma//Adenomas//Adenoma, Follicular//Adenomas, Follicular//Follicular Adenoma//Follicular Adenomas//Adenoma, Trabecular//Adenomas, Trabecular//Trabecular Adenoma//Trabecular Adenomas//Adenoma, Monomorphic//Adenomas, Monomorphic//Monomorphic Adenoma//Monomorphic Adenomas//Adenoma, Papillary//Adenomas, Papillary//Papillary Adenoma//Papillary Adenomas//Adenoma, Basal Cell//Adenomas, Basal Cell//Basal Cell Adenoma//Basal Cell Adenomas//Adenoma, Microcystic//Adenomas, Microcystic//Microcystic Adenoma//Microcystic Adenomas

Expression Detail

GEO ID: GSE25609 Description: Plasma microRNA profiling by microarray elucidates several candidate biomarkers for colorectal cancer screening Experimental Design: Cancer vs Control Case Disease Type: Advanced Adenoma Case Disease SubType: NA Case Sample: Advanced Adenoma Post surgery Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand AEN chr15 88621337 88632281 + CD276 chr15 73683966 73714514 + FAM168B chr2 131047876 131093460 - GIPC1 chr19 14477760 14496149 - IGF2BP3 chr7 23310209 23470491 - ILF3 chr19 10654261 10692417 + JRK chr8 142657460 142681968 - KCTD21 chr11 78171249 78188626 - KIAA0232 chr4 6781375 6884170 + MET chr7 116672196 116798386 + MTCL1 chr18 8705661 8832778 + NRBP1 chr2 27427790 27442259 + PA2G4 chr12 56104537 56113910 + PAK1 chr11 77321707 77474635 - PLK2 chr5 58453982 58460139 - PPP1CC chr12 110719680 110742939 - PRLR chr5 35048756 35230487 - RHOU chr1 228735479 228746664 + SNX27 chr1 151612006 151699091 + SOX11 chr2 5692384 5701385 + SS18 chr18 26016253 26091217 - STRBP chr9 123109500 123268586 - TMX4 chr20 7977346 8019805 - TXN2 chr22 36467046 36481640 - WASL chr7 123681943 123749003 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000894 chr19 12825634 12826553 - hsa_circ_0000540 chr14 55799534 55821940 + hsa_circ_0001005 chr2 53921020 53978078 - hsa_circ_0001168 chr20 47691321 47707559 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC009133.5 chr16 29808679 29812227 + AC023509.1 chr12 53441741 53467528 + AC095055.1 chr4 151139991 151141103 + AC239868.1 chr1 149861271 149862504 + CYTOR chr2 87454781 87636740 + KCNQ1OT1 chr11 2608328 2699994 - LINC01578 chr15 92819540 92899701 + MIR4435-2HG chr2 111006015 111523376 - MIR663AHG chr20 26167817 26251546 - NEAT1 chr11 65422774 65445540 + OIP5-AS1 chr15 41283990 41309737 + SNHG16 chr17 76557764 76565348 + SNHG20 chr17 77086716 77099902 + Display:

Experiment Detail

GEO ID: GSE25609 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 826 Sample treatment protocol: Briefly, samples were centrifuged at 1,600×g for 10 min at 4 ºC to spin down blood cells, and plasma was transferred into new tubes, followed by further centrifugation at 16,000×g for 10 minutes at 4ºC to completely remove cellular components. RNA Extract protocol: NA RNA library preparation protocol: Biotinylated cDNA were prepared with the Illumina® TotalPrep™ RNA Amplification Kit (Ambion).

Reference

PMID: 23267864 Title: Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study Author: Gir¨¢ldez MD, Lozano JJ, Ram¨ªrez G, Hijona E, Bujanda L, Castells A, Gironella M Journal: Clin Gastroenterol Hepatol. 2013 Jun;11(6):681-8.e3. Description: We investigated whether plasma levels of miRNA can differentiate patients with CRC from healthy individuals. We also investigated whether plasma samples from patients with premalignant neoplastic lesions, such as advanced adenomas (AAs), also had a different expression pattern of miRNAs.